gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
Trade name: Primovist
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
1
Earliest trial started Apr 27, 2018 (NCT04288323)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Unspecified targetContrast agent
contrast agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06319027 | Phase 2 | Apr 11, 2024 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
| NCT04870645 | N/A | Mar 30, 2021 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT04288323 | Phase 4 | Apr 27, 2018 | Bayer, Icahn School of Medicine at Mount Sinai, University of California, San Diego |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2021 |
| Bayer | For profit | 1 | 0 | 1 | 2018 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of California, San Diego | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2021 |
6 organizations
Page 1 / 1